Quarterly report pursuant to Section 13 or 15(d)

COMMITMENTS AND CONTINGENCIES (Details Narrative)

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)		3 Months Ended
	Jan. 11, 2022	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2019	Dec. 10, 2015
Renumeration amount		$ 3,000
Consideration amount	$ 657,640	502,989
First payment owed	$ 145,000	5,046
Attorney's fees		$ 235,886
Interest rate		10.00%
Accrual of loss on contingency		$ (322,000)
Compensation for services, description		As of May 14, 2021, the Company has entered into four consulting agreements. In compensation for services: (i) one consultant shall receive a renumeration amount of $10,000-$12,500 per month and has earned 1% of the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals as of May 7, 2021 based on FDA clearance of Company’s IND application; consulting agreement terminated in April 2021 (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; (iii) two consultants shall receive common stock equivalent to $3,750 on the last day of each month; and (iv) one consultant shall receive a remuneration amount of $3,500 per month
Common stock, par value		$ 0.001	$ 0.001	$ 0.001
Charles River Laboratories, Inc. [Member]
Remaining commitment		$ 28,936	$ 28,936
BICX Holding Company LLC [Member]
Common stock issued upon convertible debt		2,227,575
Convertible Promissory Note					$ 4,160,000
Conversion agreement description		Pursuant to the Conversion Agreement, BICX has agreed that the Total Interest Payment (as defined in the Conversion Agreement) that would have been due under the Note, in the amount of $1,138,157, will be reflected on the Company’s financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned prior to closing, then on or before such date that is no later than twelve (12) months from the date of such termination or abandonment
Issuance price		$ 2.00
Amount due to investor		$ 1,138,157
Board Member [Member]
Stock options grant			4,000
Term of options		3 years
Receive common stock equivalent		$ 5,000
Consulting services valued		12,428
Alpine Creek [Member]
Royalty due		91	$ 91	$ 91
Total consideration amount		1,531,926
Payables to Alpine Creek						$ 1,215,000
Paid to Alpine Creek		$ 1,620,000
Payable per treatment sold						$ 100
Profit holding percentage						50.00%